eFFECTOR Therapeutics

EFTR · OTC

$0.0002+$0.00 (+0.00%)TodayMarket closed · Oct 20, 10:26 AM ET

No price history for this range.

EFTR analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Sep 26, 2024

Bull case

eFFECTOR Therapeutics Inc. has demonstrated significant clinical success with its selective translation regulator inhibitor, tomivosertib, particularly noted for its superior objective response rate (ORR) in the ZFA regimen, surpassing the 20% ORR from the MAINTAIN study while treating a patient population with less prior intervention. Furthermore, tomivosertib has shown promise in extending median progression-free survival (mPFS) in previously non-responsive metastatic NSCLC patients when combined with anti PD-(L)1 therapies, indicating its potential in enhancing treatment efficacy. The company’s positive clinical outcomes and the favorable adverse event profile of tomivosertib, tested in over 200 patients, underscore a strong foundation for further development and advancement into more advanced trials.

Bear case

eFFECTOR Therapeutics Inc. is projected to experience a significant increase in net loss, with an expected loss of $5.08 per share for the full year 2024 compared to a loss of $0.66 per share for 2023. The company faces multiple substantial risks, including negative clinical results and the potential inability to advance key drug candidates into pivotal trials, which could hinder regulatory approval and commercial success. Additionally, concerns regarding partnership stability, share price delisting risk, and potential dilution pose further challenges to the company's financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.